Venus Remedies has received Good Manufacturing Practices (GMP) certification for its facilities from the Ministry of Health, Libya.
Saransh Chaudhary, CEO of Venus Medicine Research Centre, said, “The GMP certification from Libya adds to Venus Remedies’ portfolio of international approvals from 25 regulators, complementing our existing certifications in Africa from Morocco, South Africa, Tanzania, Kenya, Uganda, Sudan and other African countries.”
Libya’s pharma imports, valued at $514 million in 2021, have grown at a rate of 2.81 per cent over the previous year. The $46.8 billion pharma market of Africa, as in 2022, is expected to grow at a CAGR of 8.3 per cent to reach $110.9 billion by 2023. This certification is a step towards enhancing the company’s presence in Africa.